Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients’ Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial

Anwar A. Jammah1*, Afshan Masood2, Layan A. Akkielah1, Shaimaa Alhaddad3, Maath A. Alhaddad4, Mariam Alharbi5, Abdullah Alguwaihes1 and Saad Alzahrani6

1 Department of Medicine, King Saud University, Riyadh, Saudi Arabia, 2 Obesity Research Center, King Saud University, Riyadh, Saudi Arabia, 3 Department of Medicine, Endocrinology Division, Ministry of Health, Kuwait City, Kuwait, 4 Faculty of Allied Health Sciences, Kuwait University, Kuwait City, Kuwait, 5 Endocrine and Internal Medicine Department, Qassim University, Buraydah, Saudi Arabia, 6 Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia

Context: Following total thyroidectomy and radioactive iodine (RAI) ablation, serum thyroglobulin levels should be undetectable to assure that patients are excellent responders and at very low risk of recurrence.

Objective: To assess the utility of stimulated (sTg) and non-stimulated (nsTg) thyroglobulin levels in prediction of patients outcomes with differentiated thyroid cancer (DTC) following total thyroidectomy and RAI ablation.

Method: A prospective observational study conducted at a University Hospital in Saudi Arabia. Patients diagnosed with differentiated thyroid cancer and were post total thyroidectomy and RAI ablation. Thyroglobulin levels (nsTg and sTg) were estimated 3–6 months post-RAI. Patients with nsTg <0.1 ng/ml were stratified based on their levels and were followed-up for 5 years and clinical responses were measured.

Results: Of 196 patients, nsTg levels were <0.1 ng/ml in 122 (62%) patients and 0.1–2.0 ng/ml in 74 (38%). Of 122 patients with nsTg <0.1 ng/ml, 120 (98%) had sTg levels <1 ng/ml, with no structural or functional disease. sTg levels >1 occurred in 26 (35%) of patients with nsTg 0.1–2.0 ng/ml, 11 (15%) had structural incomplete response. None of the patients with sTg levels <1 ng/ml developed structural or functional disease over the follow-up period.

Conclusion: Suppressed thyroglobulin (nsTg < 0.1 ng/ml) indicates a very low risk of recurrence that does not require stimulation. Stimulated thyroglobulin is beneficial with nsTg 0.1–2 ng/ml for re-classifying patients and estimating their risk for incomplete responses over a 7 years follow-up period.

Keywords: highly sensitive thyroglobulin, differentiated thyroid cancer, stimulated thyroglobulin, reclassification, dynamic risk assessment, DTC recurrence, non-stimulated thyroglobulin
INTRODUCTION

With marked increase in the incidence rates, thyroid cancer has been deemed to be the most rapidly growing endocrine cancer with an annual increase of 3% (1). This increasing tendency, in the rate of thyroid cancer, has also been reported in Saudi Arabia. The annual Saudi tumor registry report in 2012 placed the prevalence of thyroid cancer at 9.9% with a male/female ratio of 0.3:1 (2–4). Patients with differentiated thyroid cancer with differentiated thyroid cancer (DTC) are commonly diagnosed with papillary thyroid cancer (PTC) (85–90%), followed by follicular thyroid cancer (FTC) (15–10%), then Hurthle thyroid cancer (1–3%), and medullary thyroid cancer (MTC) (3–5%) (5).

Although the thyroid tumors have a good prognosis, the rate of recurrence still remains high and consequential at 10–20% (6). In several instances, these recurrences are detected within the first 6 years post thyroidectomy; however, some appear decades later (6).

Currently, the standard initial treatment for patients with high-risk pathology and some with intermediate American Thyroid Association (ATA) is total thyroidectomy, followed by radioactive iodine I-131 remnant ablation (RAI) (7).

Following total thyroidectomy and RAI ablation, serum Tg levels should be undetectable to assure patients that they are excellent responders and at very low risk of recurrence which is observed in majority of them (8). According to the European and American Thyroid Association guidelines, patients with DTC can be considered free of disease when there is no clinical evidence of the tumor, no evidence of the tumor on imaging, and negative serum thyroglobulin (Tg) level. The Tg levels should be undetectable during TSH suppression therapy, i.e. non-stimulated Tg (nsTg) and/or following stimulation (sTg) measurement (9–12). Because of its high cellular specificity, any change in Tg levels serve as a sensitive biomarker for detecting the presence of residual, or recurrent disease in patients with DTC (10). sTg, which is considered to be a more sensitive measure of tumor marker, can be measured either after the withdrawal of thyroxine or after the use of recombinant human TSH (rhTSH) injections. Both are comparable tests (6, 11). The value of sTg <1 ng/ml, represents a very low risk of recurrent/persistent disease (13). In some studies, specifically in low-risk patients, sTg has not played a major role (14–17). In contrast, other studies have concluded that Tg assay, during thyroid hormone suppression (suppressed Tg), might fail to detect thyroid cancer recurrence, residual tumor, or metastasis (18). sTg >2 µg/L identified all patients with metastasis (19). Nevertheless, a single rhTSH-stimulated serum Tg <0.5 ng/ml in the absence of anti-Tg antibody has an approximately 98.0–99.5% likelihood of identifying patients that are completely free of the tumor at follow-up (20).

Recently, Tg measurement using high-sensitive assays have proven to be effective at reducing the need for Tg stimulation (11, 15). As confirmed by many studies using different high-sensitive assays, few patients with undetectable suppressed Tg have a pathological Tg response (>1 ng/ml) to stimulation (21, 22). They recommended that these patients need to be monitored through regular measurements of the suppressed Tg level and periodic neck ultrasonography. An increase in the levels of suppressed Tg should prompt further investigation (23). Further, suppressed Tg monitoring would prevent the dependence on the use of fixed cut-off criteria, as revealed in another study (24).

In this study we hypothesized that an undetectable Tg level in patients with DTC following total thyroidectomy and RAI ablation would ensure the absence of recurrence and avoid the use of stimulated Tg. It will also enable the establishment of a cut-off value for the suppressed Tg that will be used to decide whether further stimulation of thyroglobulin is needed.

MATERIALS AND METHODS

Study Population

Prior to the recruitment, all the study procedures and protocols were reviewed and approved by the Institutional Review Board of the College of Medicine, King Saud University. Written informed consent was obtained from all the participants. We screened all the patients with confirmed DTC who were being followed-up at the thyroid cancer outpatient clinics at the King Khaled University Hospital in King Saud University Medical City, in Riyadh between February 2011 to February 2015. Their medical histories and physical examinations were recorded, and they underwent complete clinical radiological evaluation and laboratory investigations.

The inclusion criteria were: 1) age >14 and <75 years; 2) confirmed diagnosis of DTC based on the final pathological report with one or more of the following high-risk features indicate the treatment with RAI ablation, according to the available guidelines at that time (17, 25): indications for RAI ablation in our study patients was tumor size >2 cm, significant lymphovascular invasions (>3), gross extra-thyroidal extension, lymph node involvement (N1); 3) treatment with total thyroidectomy, followed by RAI ablation with iodine 131 (I-131). The decision for the dose was made by the thyroid cancer consultants based on a fixed dose approach, according to multiple variables including the pathology report, age of the patient, extension of the surgery, and the surgeon’s experience, and no pre-therapy scan was performed; and 4) non-stimulated or basal serum Tg (nsTg) level (<0.1) to <2 ng/ml, 3–6 months post RAI ablation.

Exclusion-criteria were: 1) age <14 years or >75 years and pregnancy; 2) those that did not require a complete surgery or RAI ablation because of the low risk disease; 3) patients who tested positive for Tg antibodies; 4) detectable persistent disease based on imaging, with positive uptake (outside the thyroid bed) in post ablation whole body scan (WBS) indicating metastasis, and/or if an ultrasound or computed tomography (CT) results showed significant remnant or suspicious lymph nodes or metastasis within 6 months of the diagnosis; and 5) patients who had highly suppressed Tg level (>2 ng/ml) 3–6 months post RAI ablation, since these indicate a high tumor marker that did not require further confirmation with Tg stimulation.
After 3–6 months following RAI ablation, the patients were stratified according to their nsTg or basal serum Tg (ng/ml) level into two groups: the first and second groups had Tg <0.1 and nsTg of 0.1–2.0 ng/ml, respectively. The serum Tg levels were measured while TSH was suppressed (0.1–0.5 µIU/ml). sTg was measured by rhTSH stimulation test protocol which required two intramuscular injections of rhTSH (thyrogen) 0.9 mg to be given on days 1 and 2. sTg was measured on day 5 (72 h after the second injection of thyrogen). The sTg test was considered to be negative when the level was <1 ng/ml and positive if >1 ng/ml. The first sTg was measured 3 to 6 months following the first RAI ablation while the second one was 5 years after the first one, for all patients.

Follow-up was performed until February 2020 every 3 to 12 months along with the laboratory investigations, including thyroid function test, and thyroglobulin and antithyroid antibodies, with a yearly neck ultrasound that was performed at the radiology department. Neck, chest, and abdominal CT scan, WBS using positron emission tomography (PET) scan, magnetic resonance imaging (MRI) of the brain, skeletal MRI, bone scan, and/or fine needle aspirations were performed for some patients with suspected structural disease.

At the end of the study in February 2020 (at least 5 years of follow-up for each patient), we classified the patients whose response to total thyroidectomy and RAI ablation concurred with ATA 2015 classification into excellent or indeterminate response, or biochemical or structural incomplete response groups (7). Excellent response was defined as negative imaging, and either nsTg <0.1 or sTg <1 ng/ml. The indeterminate response was defined as non-specific finding on imaging, faint uptake in the thyroid bed in RAI scan, nsTg 0.2–1.0, sTg 1.1–10.0, or stable anti-Tg antibodies or declining levels with the absence of structural or functional diseases. The biochemical incomplete response was defined as negative imaging and nsTg ≥1 or sTg ≥10 or rising anti-Tg antibody levels. The structural incomplete response was defined as structural or functional evidence of disease with any Tg level with or without anti-Tg antibodies.

### Laboratory Investigations

Laboratory investigations were conducted to measure serum Tg, TSH, FT4, and anti-thyroglobulin antibodies (ATg) levels. Serum concentration of Tg, TSH, and FT4 were measured by electrochemiluminescence immunoassay (ECLIA) system assay (Cobas, Roche Diagnostics, Germany). The detection limit of serum Tg was 0.04–500 ng/ml, and for TSH and FT4 assays, these were 0.005 µIU/ml and 0.023 ng/dl, respectively. The manufacturer’s reference range for TSH was 0.27–4.20 µIU/ml and for FT4 was 12–22 pmol/L (0.93–1.7 ng/dl). According to the manufacturer’s protocol, the reference ranges for all thyroid parameters were determined in 2003/2004 at the Universitätsklinikum Leipzig, Leipzig, Germany, from serum specimens collected from 870 blood donors. ATg were measured by enzyme-linked immunosorbent assay (ELISA) (INOVA Diagnostic, Ingbert, Germany), normal ranged from 0.0 to 0.6 units.

### Statistical Analysis

The IBM SPSS Statistics for Windows, version 20 (IBM Corp., Armonk, N.Y., USA) was used for the data analysis. Data are presented as mean, standard deviation, and percentage distribution. Independent t-test was used when the data were continuous and normally distributed. The chi-square test analysis was used for categorical data. The spearman’s correlation test was used to determine the association among non-parametric continuous variables.

### RESULTS

Of 314 patients that were screened, 196 met our inclusion criteria. Subjects’ baseline demographics and clinical variables are summarized in Table 1. The majority of patients were females (n =161). The mean (± SD) age of the participants

| TABLE 1 | Baseline characteristics. |
|----------|--------------------------|
|          | Overall                  | Suppressed thyroglobulin (nsTg) ng/mL |
|          |                          | Group 1 <0.1 | >0.1-2 |
|          |                          | Group 2 >0.1–0.4 | Group 3 0.5–1.0 | Group 4 >1.0 |
| Patients n | 196                        | 122 | 40 | 17 | 17 |
| Gender—n(%) | Male                      | 35 (17.9) | 25 (20.5) | 5 (12.5) | 3 (17.6) | 2 (11.8) |
|            | Female                    | 161 (82.1) | 97 (79.5) | 35 (87.5) | 14 (82.4) | 15 (88.2) |
| Age—years (SD) | 45 (12)                  |                |                |                |                |                |
| Pathology n (%) | PTC                      | 175 | 118 | 34 | 12 | 11 |
|              | FTC                       | 17 | 3 | 6 | 3 | 5 |
|              | HCC                       | 4 | 1 | 0 | 2 | 1 |
| sTg—n(%) | <1                        | 168 (85.7) | 120 (98) | 34 (85%) | 48 (85%) | 34 (85%) |
|           | =>1                       | 28 (14.3) | 2 (2) | 6 (15) | 6 (35.3) | 14 (82.4) |

Baseline characteristics of 196 patients following total thyroidectomy and radioactive iodine (RAI) ablations, with suppressed thyroglobulin below 2 ng/ml, were included from February 2011 to February 2015, with their non-stimulated and stimulated thyroglobulin measured 3–6 months following RAI ablation. PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; HCC, Hurthle cell carcinoma; nsTg, non-stimulated thyroglobulin; sTg, stimulated thyroglobulin.
was 45 (± 12) years. The predominant histopathological finding for our patients was papillary thyroid cancer (n=175), with the following subtypes (classical n=112 64%, follicular variant n=49 28%, tall cell n=5 cell 3%, other variants n=9 5%) followed by follicular thyroid cancer (n=17), and Hurthle cell cancer (n=4). Indications for RAI were mainly lymph node involvement (N1a or N1b) in 109 patients (56%), T2 in 38 patients (19%), T3 in 52 patients (26.6%), and T4 in 14 patients (7%). Of the 196 patients, 13 (6.6%) had significant lymphovascular invasion while 3 had gross extra-thyroidal extension. More than half of the patients, 131/196 patients (67%), were treated with 3.7 GBq (100 mCi) RAI ablation; 41 patients (21%) were treated with 1.11 GBq (30 mCi), while 24 patients received 5.55 GBq (150 mCi).

At 3–6 months post RAI therapy, the majority of the patients [n=122 (62.2%)] had basal suppressed serum or nsTg values of <0.1 ng/mL, in the majority of them [n=120 (98%)] also had sTg levels <1 ng/mL. Seventy four patients had nsTg values between 0.1 and 2.0 ng/mL and 26 of them (35%) had sTg >1 ng/mL (Figure 1). A strong correlation was found between the initial levels of nsTg and sTg at both the initial suppressed thyroglobulin (nsTg) <0.1 ng/mL and >0.1–2.0 ng/mL (r = 0.275, r = 0.821, p <0.01).

All the patients were followed-up from February 2011 until February 2020; median follow-up duration was 84 months.

**Patients With nsTg Level <0.1 ng/mL**

Only 2 patients out of 122 (1.6%) had positive sTg (Table 2 and Figure 2A). The first patient was a 32-year-old woman at diagnosis. Her initial pathology was 7 cm classical variant PTC with microscopic extra-thyroidal extension, positive surgical margins with >4 lymphovascular invasions, and 9 out of 33 lymph-nodes were positive at different levels of the neck, T4N1bM0. She received 5.55 GBq (150 mCi) RAI ablation initially. Her measured nsTg levels rose slowly during the 8-year follow-up to reach 3.6 ng/mL and the last sTg level was 11.2 ng/mL; however no structural disease was found. The second patient was 61-year-old man at diagnosis, with 7 cm encapsulated cystic PTC, a mixture of follicular and classical variant, and no extra thyroidal or lymphovascular invasion noted. The patient had only two negative lymph nodes resected (Nx). He received 3.7 GBq (100 mCi) RAI ablation, the nsTg level decreased over the 7-year follow-up period. The last sTg level was 1.4 ng/mL, and his last two nsTg levels were each <0.1 ng/mL, 6 months apart.

The clinical responses of the patients were assessed (Table 3, Figure 3) and we found that none of the patients had structural incomplete response, while one patient had biochemical incomplete response.

Tg values 0.1–2.0 ng/mL occurred in 74 patients overall and 26 (35%) had positive sTg (>1 ng/mL). Among the 74 patients, nsTg levels between 0.1 and 0.4 ng/mL were found in 40 patients, and 34 (85%) of these had negative sTg. nsTg levels were between 0.5 and 1 ng/mL in 17 patients, 11 (65%) of whom had negative sTg. There were 17 patients with nsTg 1–2 ng/mL, and most of them [14 (82%)] had positive sTg >1 ng/mL.

**TABLE 2 | Initial and Follow-up Stimulated Thyroglobulin.**

| Group | Initial suppressed thyroglobulin (nsTg) ng/mL | >0.1–2 |
|-------|--------------------------------------------|-------|
|       | Group 1 <0.1 | Group 2 >0.1–0.4 | Group 3 0.5–1.0 | Group 4 1.0–2.0 |
| Patients n | 196 | 122 | 40 | 17 |
| Initial sTg n (%) | <1 | 168 (85.7) | 120 (98) | 34 (85) | 11 (64.7) | 3 (17.6) |
| =>1 | 28 (14.3) | 2 (2) | 6 (15) | 6 (35.3) | 14 (82.4) |
| Follow up sTg- n(%) | <1 | 172(87.8) | 121 (99) | 26 (87.5) | 13 (76) | 3 (17.6) |
| =>1 | 24(12.2) | 1(1) | 5 (12.5) | 4 (24) | 14 (82.4) |

Follow-up stimulated thyroglobulin results of the 196 patients following total thyroidectomy and radioactive iodine (RAI) ablation, with suppressed thyroglobulin <2.0 ng/mL. They were grouped according to the non-stimulated thyroglobulin levels 3–6 months following RAI ablation. Initial stimulated Tg (sTg) were measured 3–6 months following the RAI ablation. Follow-up sTg was measured after 5 years from the initial sTg measurement. nsTg, non-stimulated thyroglobulin; sTg, stimulated thyroglobulin.
Patients With nsTg Level 0.1–0.4 ng/ml

Overall, 34 out of 40 patients had sTg <1 ng/ml (Table 2 and Figure 2B), and all of them had excellent response during the whole follow-up period (Table 3 and Figure 3). The six (15%) patients with positive sTg levels were diagnosed with structural incomplete response during the first year of the follow-up and both of them had cervical lymph-nodes and required surgery. One patient continued to have biochemical incomplete response. Two patients had indeterminant response. The last patient was reclassified to excellent response during the follow-up.

Patients With nsTg Levels From 0.5 to 1.0 ng/ml

Out of 17 patients, 11 (65%) had negative sTg <1 ng/ml, and all had excellent response to the end of the follow-up (Table 2 and

---

### TABLE 3 | Clinical response of the patients.

| Response | Excellent | Indeterminant | Biochemical incomplete | Structural incomplete |
|----------|-----------|---------------|------------------------|----------------------|
| Group 1 <0.1 ng/ml | 172 (88%) | 4 (2%) | 11 (6.6%) | 9 (4.6%) |
| Group 2 >0.1–0.4 ng/ml | 121 (99%) | 0 | 1 (1%) | 0 |
| Group 3 0.5–1.0 ng/ml | 3 (87.5%) | 0 | 1 (2.5%) | 2 (5%) |
| Group 4 1.0–2.0 ng/ml | 13 (76%) | 0 | 1 (1.6%) | 21 (12%) |

| Site of structural disease | Cervical | Mediastinum | Lung | Other |
|---------------------------|----------|------------|------|-------|
| Group 1 <0.1 ng/ml | 6 | 0 | 0 | 0 |
| Group 2 >0.1–0.4 ng/ml | 0 | 1 | 0 | 0 |
| Group 3 0.5–1.0 ng/ml | 2 | 1 | 0 | 0 |
| Group 4 1.0–2.0 ng/ml | 2 | 1 | 0 | 0 |

Clinical responses and the sites of the structural disease at the end of the study in February 2020, with median follow up of 84 months. 196 patients following total thyroidectomy and radioactive iodine (RAI) ablation were included from February 2011 to February 2015 with suppressed thyroglobulin <2.0 ng/mL. They were grouped according to the suppressed thyroglobulin levels 3–6 months following RAI ablation. nsTg, non-stimulated thyroglobulin.
Six patients out of 17 (35%) had positive sTg, one patient had cervical lymph-nodes metastasis required multiple surgeries (3 over a 6-year follow-up). One patient had mediastinal mass required multiple RAI ablation (two times) with a total dose of 5.55 GBq (150 mCi), one patient had biochemical incomplete response and one had an indeterminant response. Two patients were reclassified to had excellent response. Of 17 patients, 13 (76%) achieved excellent response by the end of the follow-up (Table 3 and Figure 3).

Patients With nsTg level 1.1–2.0 ng/ml
Out of 17 patients, 14 (82%) had sTg >1 ng/ml (Table 2, and Figure 2D); 8 patients continued to have biochemical incomplete response, 5 (29%) developed structural incomplete response, 1 of them developed lymph nodes metastasis in the cervical area, 1 patient developed lymph nodes metastasis in the cervical and mediastinal areas, 2 patients had lung metastasis, and 1 patient had metastasis in multiple sites (the lung, bone, and liver). The first two patients underwent surgical treatment while the other three patients received multiple RAI ablations; one of them was administered a tyrosine kinase inhibitor. Three patients with sTg <1 ng/ml were followed-up for 6, 8, and 9 years; none of them developed structural or biochemical incomplete response (Table 3 and Figure 3).

DISCUSSION
DTC is known to recur after the initial treatment. Although the rate of recurrence is low, it necessitates long-term follow up (26). The focus of this study was to evaluate the utility of sTg with suppressed or nsTg <0.1–2.0 ng/ml in DTC patients who were followed-up for 7 ± 2 years following total thyroidectomy and RAI ablation, to detect disease recurrence.

In our study, we observed a low basal undetectable nsTg in 122 patients. The levels of sTg remained undetectable (<1 ng/ml) in 121 patients (99%) and almost all had an excellent response at the end of the follow-up, with only one having a biochemical incomplete response. This finding indicates that patients with DTC with nsTg <0.1 ng/ml have a very low risk of recurrence; hence, it would be adequate to monitor these patients with an annual nsTg along with a periodic neck ultrasound as increasing serum nsTg levels are early and reliable indicators of recurrent disease (27). The finding also suggests that sTg testing does not change the overall management of DTC and is not required in this group of patients. Our findings are in line with previous studies, which have also proposed the use of highly sensitive Tg assay in low risk patients (23, 28). Our findings are in line with those of two other studies, which showed that patients with DTC having serum nsTg levels <0.1 ng/ml, are at low risk of recurrence, and that stimulated testing neither changes the management nor is needed in this group of patients (12, 23).

Rosario et al. showed comparable data with the same number of patients, in a retrospective study (n=194). We reached the same conclusion that patients with DCT, with a suppressed Tg level <0.1 ng/ml rarely have an rhTSH-stimulated Tg >1 ng/ml. The previous study recommended monitoring of such patients with a suppressed Tg level and periodic neck ultrasonography (23).

sTg levels in our patients with nsTg level between 0.1 and 2.0 ng/ml 3 to 6 months after RAI ablations was sufficient to reclassify the patients from indeterminant response and biochemical incomplete response groups to the excellent response in a large group of patients who were confirmed over the 7 ± 2 years of follow-up period. These findings were consistent with those in some previous studies; however, the classification and reclassification approach and timing of sTg measurement differ. In some of the studies, the patients were
classified either post-operatively, before RAI ablation, at the time of ablation, and a few months post RAI ablation in few studies, including ours. Most of the studies used the new and the old ATA classification while few used other classifications like the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) (26, 29–32). In our study, we used the new ATA classification to classify and reclassify the patients 3–6 months post RAI ablation, and we continued to reclassify them during the minimum 5-year follow-up.

During the last four decades, Tg has been measured using three different methodological approaches: radioimmunoassay (RIA), immunometric assays, and liquid chromatography-tandem mass spectrometry (LC-MS/MS) that was developed in 2008. These assays differ mainly in their functional sensitivity and propensity for HAMA and Tg Ab interference (20, 24, 33). Second-generation assays have functional sensitivity of ≤0.10 µg/L. Increasingly, laboratories are replacing the first-generation tests with Tg 2G IMA measurements. This is because of their superior functional sensitivities (34–36). The availability of these methods with higher functional sensitivity allows the measurements of Tg with good reliability, the surveillance of recurrences in apparently disease-free treated patients possible (23).

CONCLUSION

In low risk thyroid cancer patients highly sensitive nsTg measurement <0.1 ng/ml identifies patients with DTC who are at a very low risk of recurrence and who do not need an sTg test. The sTg was able to reclassify a large group of patients with nsTg level 0.1 to 2 ng/ml and predict their response during a median follow up of 7 years. These findings enhance the use of sTg in this group of patients with DTC as well as dynamic risk assessment.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Health Sciences Colleges Research on Human Subjects King Saud University College of Medicine, IRB Approval of Research Project No. E-20-4877. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

All authors contributed to the article and approved the submitted version.

REFERENCES

1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. Jama (2017) 317:1338–48. doi: 10.1001/jama.2017.2719
2. Jazieh AR, Da’ar OB, Alkaiyat M, Zaathreh YA, Saad AA, Bustami R, et al. Cancer Incidence Trends From 1999 to 2015 And Contributions Of Various Cancer Types To The Overall Burden: Projections To 2030 And Extrapolation To 2050. Cancer Manag Res 11 (2019) 9665–74. doi: 10.2147/CMAR.S222667
3. Bazarbashi S, Al Eid H, Minguet J. Cancer Incidence in Saudi Arabia: 2012Data from the Saudi Cancer Registry. Asian Pac J Cancer Prev APJCP (2017) 18:2437–44. doi: 10.22034/APJCP.2017.18.9.2437
4. Hussain F, Iqbal S, Mehmoood A, Bazarbashi S, ElHassan T, Chaudhri N. Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000-2010. Hematol/Oncol Stem Cell Ther (2013) 6:58–64. doi: 10.1016/j.hemonc.2013.05.004
5. Fagin JA, Wells S AJr. Biologic and Clinical Perspectives on Thyroid Cancer. New Engl J Med (2016) 375:1054–67. doi: 10.1056/NEJMra1501993
6. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent iodotide or postoperative thyroid remnants after either recombinant human thyroid tropin or thyroid hormone withdrawal. J Clin Endocrinol Metab (2009) 94:4171–9. doi: 10.1210/jc.2009-0869
7. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid Off J Am Thyroid Assoc (2016) 261–133. doi: 10.1089/thy.2015.0020
8. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab (2001) 86:1447–63. doi: 10.1210/jcem.86.4.7407
9. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (2003) 58:138–40. doi: 10.1046/j.1365-2265.2003.01681.x
10. Giovanella L, Ceriani L, Maffioli M. Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head Neck (2010) 32:568–71. doi: 10.1002/hed.21214
11. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab (2003) 88:1433–41. doi: 10.1210/jc.2002-021702
12. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human th-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab (2007) 92:82–7. doi: 10.1210/jc.2006-0993
13. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Surveillance for the diagnosis and monitoring of thyroid disease. Thyroid (2003) 13:3–126. doi: 10.1089/105072503321086962
15. Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, Fleisher M, et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. *J Clin Endocrinol Metab* (2004) 89:6010–6. doi: 10.1210/jc.2003-031573

16. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. *Clin Endocrinol* (2007) 67:434–41. doi: 10.1111/j.1365-2265.2007.02907.x

17. Pacini F, Schlumberger M, Drale H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* (2006) 154:787–803. doi: 10.1530/eje.1.02158

18. Westbury C, Vini L, Fisher C, Harmer C. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. *Thyroid Off J Am Thyroid Assoc* (2000) 10:171–6. doi: 10.1089/thy.2000.10.171

19. Black EG, Sheppard MC. Serum thyroglobulin measurements in thyroid cancer: evaluation of ‘false’ positive results. *Clin Endocrinol* (1991) 35:519–20. doi: 10.1111/j.1365-2265.1991.tb00937.x

20. Kloos RT. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. *J Clin Endocrinol Metab* (2010) 95:5241–8. doi: 10.1210/jc.2010-1500

21. Rosario PW, Borges MA, Fagundes TA, Franco AC, Purisch S. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroidin and negative neck ultrasound? *Clin Endocrinol* (2005) 62:121–5. doi: 10.1111/j.1365-2265.2005.02212.x

22. Persson AC, Jager PL, Sluter WJ, Plukker JT, Wolffenbuttel BH, Links TP. A sensitive Tg assay or rhTSH stimulated Tg: what’s the best in the long-term follow-up of patients with differentiated thyroid carcinoma? *PloS One* (2007) 2:e816. doi: 10.1371/journal.pone.0000816

23. Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays? *Clin Endocrinol* (2008) 68:338–42. doi: 10.1111/j.1365-2265.2007.03043.x

24. Spencer CA, Bergoglio LM, Kazarosyan M, Fateni S, Lo Presti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. *J Clin Endocrinol Metab* (2005) 90:5566–75. doi: 10.1210/jc.2005-0671

25. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: official journal of the American Thyroid Association. *Thyroid* (2009) 19:1167–214. doi: 10.1089/thy.2009.0110

26. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghesuein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system: official journal of the American Thyroid Association. *Thyroid* (2010) 20:1341–9. doi: 10.1089/thy.2010.0178

27. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. *Clin Chem Lab Med* (2008) 46:1067–73. doi: 10.1515/CCLM.2008.212

28. Flores-Rebollar A, Perez-Diaz I, Lagunas-Barcenas S, Garcia-Martinez B, Rivera-Moscoco R, Fagundo-Sierra R. Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk? *Acta Otorinolaringol Ital* *Off Gifaco* (2018) 38:188–93. doi: 10.14639/0392-100X-1494

29. Rosario PW, Furtado Mde S, Mourao GF, Calsohari MR. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low. *Thyroid Off J Am Thyroid Assoc* (2015) 25:1243–8. doi: 10.1089/thy.2015.0294

30. Hasbek Z, Turgut B, Kilici F, Altuntas EE, Yucel B. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer. *Asian Pac J Cancer Prev APJCP* (2014) 15:2523–7. doi: 10.7314/APJCP.2014.15.6.2523

31. Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, et al. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. *Endocrine* (2016) 54:467–75. doi: 10.1007/s12020-015-0823-3

32. Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. *Clin Endocrinol* (2012) 77:132–8. doi: 10.1111/j.1365-2265.2012.04342.x

33. Miyuchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. *Thyroid Off J Am Thyroid Assoc* (2011) 21:707–16. doi: 10.1089/thy.2010.0355

34. Hay ID, Grant CS, van Heerden JA, Goellner JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. *Surgery* (2008) 144:980–7; discussion 987–8. doi: 10.1016/j.surg.2008.08.035

35. Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (second of two parts). *Rev Endocr Med* (1979) 301:307–14. doi: 10.1056/NEJM197908303010605

36. Angell TE, Spencer CA, Rubino BD, Nicollot LF, Lo Presti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. *Thyroid Off J Am Thyroid Assoc* (2014) 24:1127–33. doi: 10.1089/thy.2013.0691

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.